Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052048 · ClinicalTrials.gov registry record
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
A clinical trial of Prostate Cancer Aggressiveness, sponsored by Immunis.AI.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT04052048: Recruiting study of Prostate Cancer Aggressiveness, sponsored by Immunis.AI.
NCT04052048 is a study of Prostate Cancer Aggressiveness that is actively recruiting participants, run by Immunis.AI. The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04052048, a study of Prostate Cancer Aggressiveness, is actively recruiting participants, sponsored by Immunis.AI.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
Primary Outcome
Collect information from repeat biopsy including any increase in gleason grade, increase in number of cores positive, and increase in % cross sectional surface area involved by tumor from the repeat biopsy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Subtraction Normalized Expression of Phagocytes Blood Test
Study Locations (1)
Michigan
- Comprehensive Urology - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2029-09-30 |
What NCT04052048 shows while recruiting
NCT04052048 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Prostate Cancer Aggressiveness appearing as the primary indexed condition, and to 1 intervention - of which Subtraction Normalized Expression of Phagocytes Blood Test is the first listed.
NCT04052048 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04052048 about?
NCT04052048 is a clinical study titled "Active Surveillance SNEP Assay Registry Trial for Prostate Cancer". A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
What is the current status of trial NCT04052048?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2019-09-09. Estimated completion is 2029-09-30.
What conditions does trial NCT04052048 study?
This clinical trial studies the following conditions: Prostate Cancer Aggressiveness.
What interventions are being tested in trial NCT04052048?
The interventions under investigation include: Subtraction Normalized Expression of Phagocytes Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04052048?
This trial is sponsored by Immunis.AI, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052048 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Aggressiveness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI